Financial Performance - The company's operating revenue for the first half of 2022 was ¥805,468,086.72, representing a 28.13% increase compared to ¥628,638,560.32 in the same period last year[23]. - The net profit attributable to shareholders was ¥108,807,447.40, which is a 51.68% increase from ¥71,733,560.08 in the previous year[23]. - The net profit after deducting non-recurring gains and losses was ¥106,544,601.29, up 61.55% from ¥65,952,847.11 year-on-year[23]. - The basic earnings per share increased by 50.71% to ¥0.2119 from ¥0.1406 in the same period last year[23]. - The total revenue for the first half of 2022 was 733,153,000,000 CNY, reflecting a year-on-year growth of 8.5%[181]. - The net profit for the first half of 2022 was 14,707,500,000 CNY, which is a 2.6% increase compared to the same period last year[181]. - The total comprehensive income for the first half of 2022 was 31.48 million, showing a significant increase compared to the previous year[185]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,960,636,781.81, a 5.32% increase from ¥1,861,536,925.53 at the end of the previous year[23]. - The total liabilities decreased to CNY 469,090,185.54 from CNY 483,440,978.67, a reduction of about 2.9%[158]. - The equity attributable to the parent company increased to CNY 1,361,074,135.35 from CNY 1,251,194,710.14, reflecting a growth of approximately 8.8%[158]. - Cash and cash equivalents decreased to CNY 413,783,337, accounting for 21.10% of total assets, down from 28.51% at the end of the previous year[63]. - Accounts receivable increased to CNY 553,419,089, representing 28.23% of total assets, with a year-over-year growth attributed to increased sales across three major business segments[63]. Business Segments and Strategy - The company focuses on three core businesses: medical, optoelectronics, and smart electrical, aiming to integrate traditional operations into advanced manufacturing[31]. - The medical business includes digital pathology systems and AI-assisted diagnostic services, enhancing capabilities through big data and AI technologies[32]. - The company plans to expand its market presence in life sciences, smart healthcare, and industrial testing sectors, leveraging its existing advantages in education[31]. - The company is gradually developing its e-commerce operations as a significant future business expansion channel[40]. - The company aims to integrate IoT technology into its epoxy insulation products, enhancing their intelligence and contributing to smart city development[40]. Research and Development - The company emphasizes technological innovation and has established research stations to maintain its competitive edge in the industry[34]. - The company accumulated over 12 invention patents, 10 utility model patents, and 17 software copyrights in the medical business segment by the end of the reporting period[50]. - The optical business segment has obtained a total of 82 invention patents and 95 software copyrights, showcasing its strong R&D capabilities[51]. - The company is focusing on R&D innovations in material technology to enhance its core insulation components for new energy applications[47]. Market and Competition - The company is a leading player in the domestic optical microscope industry, providing better cost-performance compared to international brands and higher overall performance than domestic competitors[46]. - The third-party diagnostic business has partnered with the National Health Commission to create a "digital pathology remote diagnosis and quality control platform," covering over 1,800 hospitals and completing 200,000 remote diagnoses in the past three years[45]. - The company is actively participating in international competition and expanding its market share in the global arena[46]. Risk Management - The management has disclosed potential risks and countermeasures in the report, emphasizing the importance of risk awareness for investors[3]. - The company faces risks from macroeconomic changes, including inflation and raw material price volatility, which may impact profit margins[82]. - The company has implemented measures to lock in exchange rates and mitigate foreign exchange risks through forward contracts[86]. Corporate Governance and Shareholder Engagement - The company emphasizes protecting the rights of investors, particularly small and medium-sized investors, by enhancing corporate governance and communication[105]. - The company held two temporary shareholder meetings with participation rates of 64.99% and 64.96% respectively, reflecting strong investor engagement[90]. - The company has introduced a stock incentive plan to motivate employees and align their interests with company performance[94]. Sustainability and Social Responsibility - The company initiated a zero-carbon construction project in its Xiamen industrial park, aiming for carbon neutrality through distributed solar power and energy storage[103]. - The company actively participates in social responsibility initiatives, including pandemic prevention and employee health protection[106]. - The company is committed to sustainable development and aims to establish a low-carbon electrical industrial park in Xiamen[105].

证券代码：300341 证券简称：麦克奥迪 公告编号：2022-031 麦克奥迪（厦门）电气股份有限公司 关于参加厦门辖区上市公司2021年年报业绩说明会暨 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 麦克奥迪（厦门）电气股份有限公司（以下简称"公司"） 已于 2022 年 04 月 07 日在巨潮资讯网（http://www.cninfo.com.cn/）披露了公司 2021 年年度报 告及其摘要，为便于广大投资者进一步了解公司 2021 年度经营情况，加强与广 大投资者的沟通和交流，公司将参加由厦门证监局、厦门上市公司协会与深圳市 全景网络有限公司联合举办的"2021 年年报业绩说明会暨投资者网上集体接待 日"活动。具体情况如下： 一、召开时间 2022 年 5 月 10 日（星期二）14:30－16:00 二、召开方式 本次活动将在深圳市全景网络有限公司提供的网上平台采取网络远程的方 式举行，投资者可登录"全景投资者关系互动平台"（http://ir.p5w.net）参与本 次互动交流。 三、出席活动的人员 公司出席本 ...

Financial Performance - The company's revenue for Q1 2022 was ¥359,515,780.05, representing a 24.09% increase compared to ¥289,716,975.56 in the same period last year[3] - Net profit attributable to shareholders was ¥45,610,282.01, up 29.71% from ¥35,164,208.37 year-on-year[3] - Basic and diluted earnings per share increased by 29.75% to ¥0.0894 from ¥0.0689 in the same period last year[3] - The total operating revenue for Q1 2022 was CNY 359,515,780.05, representing an increase of 24.1% compared to CNY 289,716,975.56 in the same period last year[15] - The net profit for Q1 2022 reached CNY 47,191,169.22, a 26.9% increase from CNY 37,206,452.32 in Q1 2021[16] - The operating profit for Q1 2022 was CNY 58,774,362.85, compared to CNY 46,618,308.49 in the previous year, marking a growth of 25.9%[15] Cash Flow - The net cash flow from operating activities decreased by 72.51% to ¥14,251,925.13, down from ¥51,846,277.69 in the previous year[3] - The cash flow from operating activities for Q1 2022 was CNY 14,251,925.13, a decrease of 72.5% from CNY 51,846,277.69 in Q1 2021[18] - The net cash flow from investment activities was 3,163,795.93 CNY, compared to a negative cash flow of -20,634,780.38 CNY in the previous year[20] - The cash flow from financing activities resulted in a net outflow of -41,107,542.52 CNY, compared to -11,846,275.79 CNY in the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,894,750,084.78, a 1.78% increase from ¥1,861,536,925.53 at the end of the previous year[3] - Total liabilities amounted to CNY 1,361,970,870.49, with current liabilities including accounts payable at CNY 151,641,669.50[12] - The total liabilities as of Q1 2022 were CNY 466,767,628.59, a slight decrease from CNY 483,440,978.67 in the previous year[14] - The company’s equity position remains strong with total equity reflecting the growth in assets and liabilities management[12] Shareholder Information - The company reported a decrease in financial expenses to CNY 2,706,932.75 from CNY 5,537,831.65 in the previous year, indicating improved cost management[15] - The top shareholder, Beijing Yizhuang Investment Holding Co., Ltd., holds 29.99% of shares, indicating significant ownership concentration[8] Operational Efficiency - The balance of accounts receivable decreased by 44.42% to ¥8,536,600 from the beginning of the period, primarily due to the use of commercial acceptance bills for payments[6] - Prepayments increased by 102.35% to ¥21,145,500, mainly due to an increase in prepayments in the medical sector[6] - The company is actively managing its receivables and inventory to optimize cash flow and operational efficiency[12] - The company experienced a significant increase in research and development expenses, totaling CNY 15,361,562.74, compared to CNY 14,839,885.57 in Q1 2021, reflecting a focus on innovation[15] Cash Reserves - Cash and cash equivalents decreased to CNY 481,328,478.98 from CNY 530,642,545.42, indicating a reduction in cash reserves[11] - The ending balance of cash and cash equivalents was 479,640,726.50 CNY, down from 486,028,671.73 CNY year-over-year[20]

Financial Performance - The company reported a significant increase in revenue, with a total of 510,163,336 shares as the basis for a cash dividend of 0.70 RMB per 10 shares[11]. - The company's operating revenue for 2021 was ¥1,464,754,512.53, representing a 23.44% increase compared to ¥1,186,600,559.29 in 2020[24]. - The net profit attributable to shareholders for 2021 was ¥178,037,346.34, an increase of 28.03% from ¥139,055,974.01 in 2020[24]. - The net profit after deducting non-recurring gains and losses was ¥152,475,339.27, up 39.85% from ¥109,027,081.61 in 2020[24]. - The net cash flow from operating activities reached ¥234,367,769.64, a 37.59% increase from ¥170,335,327.65 in 2020[24]. - The total assets at the end of 2021 were ¥1,861,536,925.53, reflecting a 9.16% increase from ¥1,705,335,204.93 at the end of 2020[24]. - The net assets attributable to shareholders increased by 15.56% to ¥1,251,194,710.14 at the end of 2021 from ¥1,082,726,957.70 at the end of 2020[24]. - The company achieved a total revenue of 1,464.75 million CNY in the reporting period, representing a year-on-year growth of 23.44%[43]. - The net profit attributable to shareholders reached 17,803.73 million CNY, an increase of 28.03% compared to the previous year[43]. - The basic earnings per share were 0.3490 CNY, reflecting a growth of 28.03% year-on-year[43]. Market Presence and Strategy - Approximately 45% of the company's total revenue comes from overseas markets, indicating a strong international presence[9]. - The company aims to enhance its market presence through strategic partnerships and regional laboratory expansions[34]. - The company is focusing on expanding its market presence and enhancing its product offerings through strategic appointments and board restructuring[132]. - The company plans to enhance market development capabilities, leveraging domestic manufacturing to deepen the domestic market and using its Hong Kong subsidiary to expand overseas[107]. - The company is actively seeking opportunities for mergers and acquisitions to bolster its market position and expand its product portfolio[132]. Innovation and R&D - The company is adapting to macroeconomic uncertainties by focusing on innovation in its two business systems: electrical energy technology and smart optical applications[5]. - The company is focused on integrating innovation in smart grids, ultra-high voltage, and artificial intelligence to adapt to environmental changes[5]. - The company is focusing on the development of digital pathology and AI-assisted diagnostic systems, which are expected to be key competitive areas in the future[34]. - The company is committed to developing smart electrical components and integrating IoT technologies to advance towards environmentally friendly and intelligent solutions[42]. - The company is developing a new generation of cervical cytology auxiliary diagnostic systems to improve diagnostic accuracy and reduce missed diagnoses[83]. - The company is investing 100 million RMB in R&D for new technologies aimed at enhancing product efficiency and sustainability[144]. Operational Risks and Challenges - The company faces risks from raw material price fluctuations, particularly in electronic components and commodities like oil and copper, which could lead to a decline in gross margin[8]. - The operational management risk has increased due to the diverse industry operations and the need for enhanced asset control and resource allocation[7]. - The company acknowledges the impact of currency exchange rate fluctuations on its revenue and profit due to foreign currency sales[9]. - The company faces risks from macroeconomic changes, including geopolitical tensions and the ongoing pandemic, which may impact its business operations[111]. - The company has implemented unified procurement strategies to enhance scale efficiency and mitigate price risks[114]. Governance and Compliance - The board of directors consists of 12 members, including 4 independent directors, ensuring compliance with legal and regulatory requirements[119]. - The company maintains complete independence in its operations, with no shared assets or financial resources with its controlling shareholder[121]. - The company has a performance evaluation and incentive mechanism in place for its directors and senior management, aligning with its development status[122]. - The company has established a comprehensive internal control system that meets national legal requirements and effectively protects investors' rights[122]. - The company has committed to improving corporate governance and compliance to protect the interests of investors, especially minority shareholders[191]. Employee and Talent Development - The company has a stable management and technical team, which contributes to its competitive advantage in the market[44]. - The company emphasizes talent development and employee satisfaction as part of its human resources strategy[191]. - The total number of employees at the end of the reporting period was 2,193, with various roles across production, sales, technical, finance, administration, and others[161]. - The company has implemented a fair and transparent compensation policy, ensuring internal equity and external competitiveness in employee salaries[163]. - The company plans to enhance its training programs, focusing on key talent development and increasing the total training hours compared to 2020[164]. Future Outlook - The company has set a revenue guidance of 1.8 billion RMB for the next fiscal year, projecting a growth rate of 20%[144]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[148]. - The company plans to pursue strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential targets[150]. - The company is likely to pursue new strategies for growth, including potential mergers and acquisitions, given the changes in its leadership and board composition[134].

麦克奥迪（厦门）电气股份有限公司 2021 年第三季度报告 证券代码：300341 证券简称：麦克奥迪 公告编号：2021-074 麦克奥迪（厦门）电气股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准 确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声 明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | 减 | | 同期增减 | | 营业收入（元） | 383,777,638.12 | 11.72% | 1,012,416,198. ...

证券代码：300341 证券简称：麦克奥迪 公告编号：2021-068 麦克奥迪（厦门）电气股份有限公司 关于参加2021年度厦门辖区上市公司投资者网上集体接待 日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 为加强与广大投资者的沟通和交流，麦克奥迪（厦门）电气股份有限公司（以 下简称"公司"）将参加由厦门证监局、厦门上市公司协会和深圳市全景网络有 限公司联合举办的"2021 年厦门辖区上市公司投资者网上集体接待日"活动， 现将本次活动的有关事项公告如下： 一、活动召开时间 2021 年 9 月 7 日（星期二）下午 15:00-17:00。 二、活动召开方式 本次活动将在深圳市全景网络有限公司提供的网上平台采取网络远程的方 式举行，投资者可登录"全景投资者关系互动平台"（http://ir.p5w.net）参与本 次互动交流。 三、出席活动的人员 公司出席本次网上集体接待日活动的人员有：公司董事长杨文良先生、财务 总监胡春华先生、董事会秘书李臻先生、监事陈培堃先生。 欢迎广大投资者积极参与。 特此公告！ 麦克奥迪（厦门）电气股份有限公司董事会 ...

Financial Performance - The company reported a revenue of 300 million RMB for the first half of 2021, representing a year-on-year increase of 15%[15]. - The net profit attributable to shareholders was 50 million RMB, up 20% compared to the same period last year[15]. - The company achieved total revenue of ¥628,638,560.32, representing a 31.10% increase compared to the same period last year[21]. - Net profit attributable to shareholders reached ¥71,733,560.08, a growth of 63.61% year-over-year[21]. - The net cash flow from operating activities surged to ¥69,971,541.98, marking a significant increase of 655.60% compared to the previous year[21]. - Basic earnings per share increased to ¥0.1406, reflecting a growth of 63.68% from the same period last year[21]. - The company reported a total comprehensive income of ¥71,420,239.30 for the first half of 2021, compared to ¥51,729,714.72 in the same period of 2020, an increase of 37.9%[165]. - The net profit for the first half of 2021 was ¥76,999,830.83, representing a 67.4% increase compared to ¥45,997,001.55 in the first half of 2020[164]. Research and Development - The company plans to invest 100 million RMB in R&D for new product development in the next fiscal year[15]. - Research and development investment rose by 17.20% to ¥32,693,778.00 from ¥27,894,855.38, indicating a commitment to innovation[60]. - The company is focusing on the development of AI diagnostic software and big data management in the field of precision medicine[45]. - The company has a research and development team in the optical business with over 100 technical personnel, covering various professional fields[55]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share by 2023[15]. - The company is focusing on global market expansion, with a diverse customer base across multiple countries, which helps mitigate market instability[31]. - The company is gradually developing its e-commerce operations, which are expected to become a significant business expansion channel in the future[36]. - The company aims to enhance its smart energy management platform, aiming for improved energy efficiency and reduced costs for clients[29]. Operational Efficiency and Management - The company's management team has over ten years of industry experience, enhancing operational efficiency and customer service[57]. - The company is focused on optimizing its organizational structure to enhance operational effectiveness and achieve maximum synergy among its business units[57]. - The company aims to enhance its management efficiency and internal structure to adapt to its expanded scale and ensure effective operations[87]. - The company acknowledges the need for continuous improvement in its technology talent structure to maintain innovation and market competitiveness[88]. Corporate Governance and Social Responsibility - The company emphasizes employee welfare by providing regular health check-ups and improving working conditions to enhance employee satisfaction and sense of belonging[104]. - The company actively fulfills its corporate social responsibility by adhering to laws, promoting employment, and contributing to sustainable development through green technology innovations[105]. - The company has established a governance structure including a board of directors, supervisory board, and various functional departments, focusing on the production and sales of epoxy insulation parts, optical microscopes, and medical testing products[196]. Risks and Challenges - Risks related to supply chain disruptions have been identified, and the company is implementing measures to mitigate these risks[15]. - The company is actively monitoring industry policy changes to minimize investment risks and ensure orderly business development[85]. - Approximately 45% of the company's revenue comes from overseas markets, exposing it to significant foreign exchange risk due to currency fluctuations[88]. Shareholder Information - No cash dividends will be distributed to shareholders for this period, as the company focuses on reinvestment[5]. - The company did not engage in any significant equity investments or asset disposals during the reporting period[73][77]. - The company has not distributed cash dividends or bonus shares for the half-year period, nor has it converted capital reserves into share capital[96]. - The total number of ordinary shareholders at the end of the reporting period was 17,053[138]. Legal and Compliance - There are ongoing significant litigation matters involving an amount of CNY 64.205 million, which is still in progress[114]. - The company has not experienced any penalties or rectifications during the reporting period[117]. - The semi-annual financial report has not been audited[112].

麦克奥迪（厦门）电气股份有限公司 2021 年第一季度报告全文 所有董事均已出席了审议本次季报的董事会会议。 公司负责人杨泽声、主管会计工作负责人胡春华及会计机构负责人(会计主 管人员)蔡亮声明：保证季度报告中财务报表的真实、准确、完整。 2021-038 2021 年 04 月 1 麦克奥迪（厦门）电气股份有限公司 2021 年第一季度报告全文 麦克奥迪（厦门）电气股份有限公司 第一节 重要提示 2021 年第一季度报告 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 2 麦克奥迪（厦门）电气股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 289,716,975.56 | 192,810,014.69 | 50.26% | | 归属于上市公司股东的净利润（元） | ...

麦克奥迪（厦门）电气股份有限公司 2020 年年度报告全文 麦克奥迪（厦门）电气股份有限公司 2020 年年度报告 2021-027 2021 年 04 月 1 麦克奥迪（厦门）电气股份有限公司 2020 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人杨泽声、主管会计工作负责人胡春华及会计机构负责人(会计主 管人员)蔡亮声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 一、 宏观经济变化导致的风险 新冠疫情导致全球经济形势充斥不确定性，经济基本面、行业格局及商业 模式均面临重构，同时也凸显传统发展模式窘境，价值链重构可能是未来一个 主基调，企业发展必须依据形式及时调整。公司两个基于平台的业务体系中， 智能电气在特高压领域，AI、大数据及光电业务板块在大数据、人工智能领域、 智慧能源板块在工业互联网领域均已经涉及且具备一定竞争优势。在此宏观背 景下，国家产业政策一定向新基建涵盖范围倾斜，将更进一步注重基础 ...

麦克奥迪（厦门）电气股份有限公司 2020 年第三季度报告全文 麦克奥迪（厦门）电气股份有限公司 2020 年第三季度报告 2020-066 2020 年 10 月 1 麦克奥迪（厦门）电气股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人杨泽声、主管会计工作负责人胡春华及会计机构负责人(会计主 管人员)蔡亮声明：保证季度报告中财务报表的真实、准确、完整。 2 麦克奥迪（厦门）电气股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 1,653,188,001.17 | | 1,621,342,843.37 | 1.96% | | 归属于上 ...